info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Balantidiasis Market Size

ID: MRFR//3303-HCR | 110 Pages | Author: Rahul Gotadki| December 2024

The parasitic nature of the ailment, in general, forms the market for balantidiasis treatment. Balantidiasis is a gastrointestinal infection resulting from the protozoan parasite Balantidium coli. The prevalence of this parasitic infection impacts the demand for effective remedies and drives studies and improvement efforts in the area of infectious diseases. Balantidiasis regularly gets smaller through the intake of infected food and water, particularly in areas with terrible sanitation. The market is encouraged via the geographical distribution of the ailment and the impact of insufficient sanitation practices on the superiority of Balantidium coli infections. The occurrence of balantidiasis exhibits international geographic versions, with higher incidences reported in positive regions. Factors that include climate, hygiene practices, and socioeconomic situations contribute to these variations, influencing the nearby demand for treatment alternatives and healthcare resources.
Balantidiasis has a zoonotic capacity, which means it can be transmitted between animals and people. This zoonotic component influences the market, requiring a One Health technique that considers both human and animal fitness. Research initiatives explore the dynamics of zoonotic transmission and its implications for remedy strategies. Public fitness interventions, such as water sanitation programs, hygiene schooling, and community awareness initiatives, affect the prevalence of balantidiasis. The market is stimulated by means of the effectiveness of those interventions in preventing and controlling the unfolding of the parasite, reducing the overall ailment burden. Travel-related risks contribute to the market dynamics of balantidiasis. Individuals visiting areas with a better occurrence of the disorder may be at an increased chance of infection. This issue affects the demand for preventive measures, including pre-tour fitness recommendations and centered treatment alternatives for returning travelers.
The immune fame of people and host susceptibility to Balantidium coli infections impact disorder effects and remedy techniques. Immunocompromised individuals might also experience extra excessive styles of balantidiasis, emphasizing the need for tailored healing strategies and issues for particularly affected person populations. Limited attention to balantidiasis in healthcare structures contributes to diagnostic demanding situations. The market is prompted by the need for increased recognition among healthcare professionals, progressed diagnostic skills, and the inclusion of balantidiasis in differential diagnoses, making sure of timely and accurate treatment. Ongoing studies on vaccine development for balantidiasis are a giant thing inside the market. While no unique vaccine is available, efforts to apprehend the parasite's biology and host immune responses contribute to the exploration of capacity vaccine applicants, shaping destiny treatment alternatives.

Covered Aspects:

Report Attribute/Metric Details
Growth Rate 7.20% (2022-2030)

Global Balantidiasis Market Overview


The balantidiasis market is anticipated to reach USD 1,743.0 Million by 2030 at 7.20% CAGR during the forecast period 2022-2030. Balantidiasis, also known as Balantidium coli infection, is a disease caused by intestinal protozoan parasite Balantidium coli.  Being transmitted through the fecal-oral route, a person acquires the disease by ingesting infective cysts from food and water contaminated by feces.


Balantidiasis Market 


The disease mainly affects large intestine. Diarrhea, weight loss, dysentery, abdominal pain, nausea, and vomiting are common symptoms for balantidiasis. The diseases is found to be prevalent in the rural areas of the developed and developing countries due to the contamination of water by the fecal matter of pigs or humans. The best remedy for the prevention of the disease are maintaining proper conditions for clean and safe drinking water. Antibiotics are most widely used for the treatment of balantidiasis.


Rising prevalence of gastrointestinal disorders, increasing number of patients and availability of treatment of balantidiasis drives the growth of the market. Additionally, the lack of hygiene and sanitation in the rural areas of developing countries is one of the many factors which affect the spread of this disease. Furthermore, rising awareness about the diseases transmitted through fecal-oral route influences the market growth. Competition among existing market players restrict the entry of new players.


Key Players in the Balantidiasis Market


Some of the key players in Balantidiasis Market are: 



  • Pfizer (U.S.)

  • Abbott (U.S.)

  • GlaxoSmithKline plc. (U.K)

  • BD (U.S.)

  • Sandoz International GmbH (Germany)

  • Amneal Pharmaceuticals LLC. (U.S.)

  • Akorn, Inc. (U.S.)

  • PharmaDerm

  • Fougera Pharmaceuticals Inc. (U.S.)


Intended Audience



  • Drug Manufacturers

  • Drug Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Balantidiasis Market Segmentation     


The balantidiasis market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of diagnosis, the market is segmented into stool examination, sigmoidoscopy, biopsy, and others.


On the basis of treatment, the market is segmented into antibiotics, appendectomy, and others. Antibiotics segment is further divided into tetracycline, metronidazole, and others.


On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.


Regional Analysis of the Balantidiasis Market   


The market for balantidiasis is found to be steady in Americas. The disease is less prevalent in North America due to high quality standards, negligible number of cases, and hygienic environment. Furthermore, emphasis on healthy life style and prevention of communicable diseases also influence the growth of the market. The prevalence of the disease is found to the higher rural South America than North American countries.


In Europe, the prevalence of balantidiasis is found to be low. Rising importance of hygienic food products and water, rigorous quality checks, rising expenditure on healthcare, and availability of funds boost the growth of the Balantidiasis Market.


In Asia Pacific, the prevalence of balantidiasis is found increasing steadily as a result of increasing prevalence of colitis, chronic diarrhea, and, deep intestinal ulcerations and poor hygienic conditions in developing countries. The infection is found to be sub clinical leading to the development of diarrhea leading to the perforation of colon. Furthermore, poor healthcare system in developing countries boost the market growth. Furthermore, the burden of gastrointestinal diseases is attributed to an increase in age, high prevalence of H pylori and lifestyle changes with risk factors such as smoking and obesity. According to the data from GLOBOCAN, in 2012, the age-standardized rate (ASR) of incidence for Asia Pacific was 15.8 and mortality was 11.7 per 100,000. According to World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million which is expected to show a massive growth to 90.4 million in 2050.


The Middle East & African region has high prevalence of balantidiasis. The infection is mainly acquired due to ingestion of food and water contaminated by cysts. Furthermore, gastrointestinal diseases are a major cause of disability in the Middle East & Africa. In Africa, the Balantidiasis Market is driven by rising demand for primary care services and improving healthcare system.


FIGURE 1: Global Balantidiasis Market by Region, 2016 (%) Balantidiasis Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation.


Balantidiasis Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Research Methodology Balantidiasis Market-


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation.


 

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.